Vera Therapeutics to file TRUTAKNA sBLA with FDA in Q4 2026
Vera Therapeutics said it will file an sBLA for TRUTAKNA with the FDA in Q4 2026, targeting 2027 approval. The company cited early commercial momentum, with shares up about 2% to ~$34.76.
Vera Therapeutics said it will file an sBLA for TRUTAKNA with the FDA in Q4 2026, targeting 2027 approval. The company cited early commercial momentum, with shares up about 2% to ~$34.76.